Acalculous Cholecystitis - Causes, Treatment & When to See a Doctor

What is Acalculous Cholecystitis?

Acalculous cholecystitis (ACC) is an inflammation of the gallbladder that occurs without the presence of gallstones—hence the term “acalculous.” It accounts for 5–10 % of all cases of acute cholecystitis, but it carries a higher risk of complications and mortality because it often develops in patients who are already critically ill or immunocompromised. The disease is thought to result from impaired blood flow (ischemia), infection, or bile stasis that damages the gallbladder wall, eventually leading to necrosis, perforation, or sepsis if untreated.

While gallstone‑related cholecystitis is common in otherwise healthy adults, acalculous cholecystitis typically appears in intensive‑care settings, after major surgery, or in severe systemic illnesses. Recognizing it early is essential because the classic “right‑upper‑quadrant pain” may be muted or masked by other life‑threatening conditions.

Common Causes

Most cases of ACC are linked to conditions that produce one or more of the following: reduced gallbladder perfusion, bile stasis, or bacterial infection. Below are the most frequently reported precipitants:

• Severe trauma or major surgery – especially abdominal, cardiac, or vascular procedures that cause prolonged hypotension.
• Critical illness – sepsis, multi‑organ failure, or acute respiratory distress syndrome (ARDS).
• Prolonged fasting or total parenteral nutrition (TPN) – lack of enteral stimulation reduces gallbladder contractions.
• Shock states – hemorrhagic, septic, or cardiogenic shock leading to gallbladder ischemia.
• Severe infections – especially with Gram‑negative bacteria (e.g., E. coli, Klebsiella) or viral hepatitis.
• Vasculitis or atherosclerotic disease – conditions like systemic lupus erythematosus or severe peripheral arterial disease that impair microvascular flow.
• Intensive‑care unit (ICU) stay > 48 hours – mechanical ventilation, sedatives, or inotropes can decrease gallbladder motility.
• Severe burns – extensive thermal injury triggers systemic inflammation and hypoperfusion.
• Cardiac bypass (CABG) surgery – post‑operative low‑output states increase risk.
• Hemolytic disorders – such as sickle cell disease, which can cause microvascular occlusion.

Associated Symptoms

Because many patients with ACC are already hospitalized for another serious condition, symptoms may be subtle or attributed to the primary illness. Commonly reported manifestations include:

• Fever (often > 38 °C) and chills
• Right‑upper‑quadrant (RUQ) tenderness or a vague abdominal ache
• Nausea and/or vomiting
• Elevated heart rate (tachycardia) without an obvious cause
• Leukocytosis – white‑blood‑cell count > 12 × 10⁹/L
• Jaundice or mild elevation of bilirubin (less common than in gallstone disease)
• Referred shoulder pain (due to diaphragmatic irritation)
• Signs of systemic inflammation: low blood pressure, altered mental status, or worsening organ function

When to See a Doctor

Anyone with a sudden onset of abdominal pain, fever, or gastrointestinal upset—especially if they have any of the risk factors listed above—should seek medical attention promptly. In the hospital setting, clinicians must maintain a high index of suspicion for ACC in patients who develop unexplained fever, RUQ tenderness, or worsening inflammatory markers.

Key situations that warrant urgent evaluation:

• Fever > 38 °C lasting more than 24 hours in a post‑operative or ICU patient.
• Acute RUQ pain that does not improve with routine analgesia.
• Rapid increase in white‑blood‑cell count or C‑reactive protein (CRP).
• New or worsening jaundice.
• Unexplained hypotension or sepsis‑like picture.

Diagnosis

Diagnosing ACC requires a combination of clinical suspicion, laboratory tests, and imaging. No single test is definitive.

Laboratory Evaluation

• Complete blood count (CBC): often shows leukocytosis.
• Liver function tests (LFTs): mild elevations in AST, ALT, and alkaline phosphatase; bilirubin may be normal or slightly high.
• Inflammatory markers: CRP and procalcitonin are frequently elevated.
• Blood cultures: indicated if sepsis is suspected; may grow Gram‑negative organisms.

Imaging Studies

• Ultrasound (US): first‑line. Findings may include a thickened gallbladder wall (> 3 mm), pericholecystic fluid, a distended gallbladder, and absent stones. The “sonographic Murphy sign” (pain on probe pressure) may be present.
• Computed tomography (CT): useful when US is equivocal or when complications (abscess, perforation) are suspected. CT can demonstrate wall edema, gas within the wall (emphysematous cholecystitis), or surrounding inflammatory changes.
• Hepatobiliary iminodiacetic acid (HIDA) scan: highly sensitive for cystic duct obstruction; a non‑filling gallbladder after 30–60 minutes strongly suggests acute cholecystitis.

Scoring Systems

Several clinical scoring tools, such as the Tokyo Guidelines severity grading, help clinicians assess disease severity and decide on operative versus conservative management.

Treatment Options

Management depends on the patient’s overall condition, the severity of gallbladder inflammation, and the presence of complications.

Initial Medical Management

• Broad‑spectrum antibiotics: start empirically (e.g., Piperacillin‑tazobactam, or a third‑generation cephalosporin plus metronidazole) to cover Gram‑negative and anaerobic bacteria. Adjust based on cultures.
• Intravenous fluid resuscitation: correct hypovolemia and support perfusion.
• Pain control: IV acetaminophen and opioids as needed, avoiding NSAIDs if renal function is compromised.
• Nasogastric decompression: may be used for severe nausea or ileus.

Surgical Intervention

Early cholecystectomy remains the gold standard when the patient can tolerate surgery.

• Laparoscopic cholecystectomy: preferred in stable patients; lower morbidity and faster recovery.
• Open cholecystectomy: reserved for perforation, gangrene, or when laparoscopic access is unsafe.
• Percutaneous cholecystostomy: image‑guided drainage of the gallbladder; indicated for critically ill patients who cannot undergo immediate surgery. It can stabilize the infection and buy time for later definitive surgery.

Post‑operative & Supportive Care

• Continue antibiotics for 4–7 days or until afebrile and inflammatory markers trend down.
• Early mobilization and respiratory physiotherapy to reduce pulmonary complications.
• Gradual re‑introduction of enteral nutrition to stimulate gallbladder motility.

Prevention Tips

While ACC cannot always be avoided, several strategies reduce risk, especially in hospitalized or high‑risk patients:

• Early enteral feeding (as soon as clinically feasible) to maintain bile flow.
• Minimize the duration of total parenteral nutrition; transition to oral/enteral routes when possible.
• Maintain adequate hemodynamic support—avoid prolonged hypotension.
• Monitor and promptly treat sepsis or systemic infections.
• Use prophylactic antibiotics judiciously in high‑risk surgeries (e.g., cardiac or vascular) according to guidelines.
• Implement “gallbladder protection” protocols in ICU: regular ultrasound surveillance for patients with > 48 hours of mechanical ventilation or vasopressor use.
• Encourage early mobilization and breathing exercises to improve overall perfusion.

Emergency Warning Signs

**References** (accessed May 2026):

• Mayo Clinic. “Acalculous cholecystitis.” mayoclinic.org
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Acute Cholecystitis.” niddk.nih.gov
• Tokyo Guidelines 2018: Clinical practice guidelines for acute cholecystitis. World Journal of Surgery.
• Cleveland Clinic. “Gallbladder Inflammation (Cholecystitis).” my.clevelandclinic.org
• World Health Organization. “Guidelines for the management of severe sepsis and septic shock.” 2021.